



SCIENTIFIC PROGRAM



EIGHTH MENACTRIMS CONGRESS FRIDAY, DECEMBER 8, 2023 MAIN HALL

08:00-09:00 Registration & Morning Coffee

09:00-10:15 **Session I: Treatment Guidelines in MS and NMOSD** *Chairs: N. Grigoriadis (GR) & J. Inshasi (AE)*

09:00-09:20	Treating MS Globally: The Challenge of Equity in MS Care	M. Zakaria (EG)
09:20-09:40	NMOSD: Updated Treatment Guidelines	D. Wingerchuk (US)
09:40-10:00	Updated 2023 MENACTRIMS Guidelines for Treatment of MS	B. I. Yamout (UAE)
10:00-10:15	<i>Panel Discussion</i>	

10:15-10:30 **Welcome and Introduction by B. Yamout (AE), President of MENACTRIMS**

10:30-11:00 **Satellite Symposium I hosted by Novartis** *Chair: J. Inshasi (AE)*

10:30-11:00	Kesimpta Real Own Experience from the UK	D. Paling (UK)
11:00-11:15	Coffee Break	

11:15-12:30 **Session II: Diagnosing MS** *Chairs: A. Siva (TR) & R. Gouider (TN)*

11:15-11:35	The Lublin Phenotypes: Is it Time for a New Mechanism-driven Classification?	F. Lublin (US)
11:35-11:55	Differential Diagnosis of Suspected MS: An Updated Consensus Approach	A. Solomon (US)
11:55-12:15	Differential Diagnosis of MS: A Case-Based Approach from the Middle East	A. Jacob (AE)
12:15-12:30	<i>Panel Discussion</i>	

12:30-13:00 **Satellite Symposium II hosted by Roche** **If Time is Brain, then it is Time for Change: Disability Prevention in MS** *Chair: A. Shatilla (AE)*

12:30-12:35	Opening and Introduction	A. Shatilla (AE)
12:35-12:45	Latest Therapeutic Updates in MS	H. Wiendl (DE)
12:45-12:55	PIRA and the Silent Progression in MS	H. Wiendl (DE)
12:55-13:00	<i>Q&A</i>	



SCIENTIFIC PROGRAM



EIGHTH MENACTRIMS CONGRESS FRIDAY, DECEMBER 8, 2023 MAIN HALL

13:00-14:30 Prayer Break (buses leave from lobby at 13:05) and Lunch

14:30-15:45

Session III: Hot Topics in MS

Chairs: C. Oreja-Guevara (ES) & A. Shatila (AE)

14:30-14:50	Pediatric MS: Differential Diagnosis and Treatment	R. Alroughani (KW)
14:50-15:10	Paradigm Shift in DMT: High Efficacy Treatments Early On	M. Tintore (ES)
15:10-15:30	Advances in MS Neuroimaging: Choroid Plexus Imaging, PET Scan and Remyelination	B. Stankoff (FR)
15:30-15:45	<i>Panel Discussion</i>	
15:45-16:15	Coffee Break	

16:15-17:15

Session IV: Oral Presentations

Chairs: M. Al-Jumrah (SA) & M. Chakra (AE)

16:15-16:25	Evolution of Brain MRI Lesions in Paediatric Myelin-Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) and Its Relevance to Disease Course	O. Abdel-Mannan (UK)
16:25-16:35	Factors Affecting Community Mobility Among Patients with Multiple Sclerosis: A Cross-Sectional Study	S.M. Mukhtar (SA)
16:35-16:45	Pediatric Onset Multiple Sclerosis in Kuwait	S.F. Ahmed (KW)
16:45-16:55	Adverse Event and Blood Pressure Profile of Disease-Modifying Therapy in Multiple Sclerosis	K.A. Jabarti (SA)
16:55-17:05	Safety and Efficacy of Disease Modifying Therapies After Switching from Natalizumab: A MENACTRIMS Observational Study	J. Al Khabouri (OM)
17:05-17:15	Serum Neurofilament Light Chain as a Biomarker for Disease Activity in Relapsing Remitting Multiple Sclerosis Patients	N. Sarhan (EG)



SCIENTIFIC PROGRAM



EIGHTH MENACTRIMS CONGRESS SATURDAY, DECEMBER 9, 2023 MAIN HALL

08:30-09:00 Registration & Morning Coffee

09:00-10:15 **Session V: MS Treatment: Past and Future** *Chairs: A. Boyko (RU) & S. Bohlega (SA)*

09:00-09:20	Treatment of MS with Beta Interferon 1b: Donald Paty 30 Years On	M. Dahdaleh (JO)
09:20-09:40	How to Assess Suboptimal Therapy in MS?	M.P. Sormani (IT)
09:40-10:00	Pregnancy and Breastfeeding in Women with MS	K. Hellwig (DE)
10:00-10:15	<i>Panel Discussion</i>	
10:15-10:30	Coffee Break	

10:30-11:00 **Satellite Symposium III hosted by Merck** *Chairs: J. Inshasi (AE) & R. Alroughani (KW)*

10:30-10:35	Welcome and Introduction	R. Alroughani (KW)
10:35-10:45	Early Treatment with Cladribine Tablets: Long-term Data and Beyond 'traditional' Endpoints	K. Schmierer (UK)
10:45-10:55	The Imperative to Target the CNS: Current and Future Perspectives	C. Oreja-Guevara (ES)
10:55-11:00	<i>Concluding Remarks and Q&A- J. Inshasi (AE)</i>	

11:00-12:15 **Session VI: European Charcot Foundation (ECF) Symposium: Smouldering Disease in MS: Evidence and Implications** *Chairs: G. Comi (IT) & S. Al-Rukn (AE)*

11:00-11:20	A Critical View of PIRA	G. Comi (IT)
11:20-11:40	Immunopathological Findings	C. Stadelman (DE)
11:40-12:00	Imaging of Chronic Inflammation and Clinical Progression	N. De Stefano (IT)
12:00-12:15	<i>Panel Discussion</i>	

12:15-12:45 **Satellite Symposium IV hosted by Biogen** *Chair: R. Alroughani (KW)*

12:15-12:40	New Heights of Efficacy and Flexibility with TYSABRI	J. Lizrova (CZ)
12:40-12:45	Q&A	
12:45-14:00	Lunch Break	



SCIENTIFIC PROGRAM



EIGHTH MENACTRIMS CONGRESS SATURDAY, DECEMBER 9, 2023 MAIN HALL

14:00-15:15		
Session VII: Future Strategies in the Treatment of MS <i>Chairs: A. Jacob (AE) & S. Khoury (LB)</i>		
14:00-14:20	Patient Reported Outcomes: A New Approach to Assess Disease Progression?	A.H. Althobaiti (SA)
14:20-14:40	Repair Promoting Strategies in MS	H.P. Hartung (DE)
14:40-15:00	Ongoing Clinical Trials in MS: What is in the Pipeline?	A. Obeidat (US)
15:00-15:15	<i>Panel Discussion</i>	
15:15-15:45		
Satellite Symposium V hosted by AstraZeneca Championing Patient Care in NMOSD <i>Chair: A. Jacob (AE)</i>		
15:15-15:40	Role of Complement in Relapses Prevention in AQP4+ NMOSD Patients	D. Wingerchuk (US)
15:40-15:45	<i>Panel Discussion</i>	
15:45-16:00	Coffee Break	
16:00-17:00		
Session VIII: Controversies in MS <i>Chairs: H. Pakdaman (IR) & A. Mahdawi (IQ)</i>		
16:00-16:25	De-escalation: Is it a Viable Option?	S. Mrabet (TN)
16:25-16:50	Tumefactive MS: Diagnosis and Mangement	S. Qureshi (SA)
16:50-17:00	<i>Panel Discussion</i>	
17:00-17:30		
Closing Ceremony and Awards Presentation by B. Yamout (AE), President of MENACTRIMS		

SCIENTIFIC PROGRAM



NURSING SESSION

SATURDAY, DECEMBER 9, 2023 MEETING ROOM 1

09:15-10:15		
Nursing Session I		
<i>Chair: J. Massouh (AE)</i>		
09:15-09:45	Prehabilitation in MS: Safeguarding Optimal Long-term Functional and Cognitive Status	P. Eelen (BE)
09:45-10:15	BTK Inhibitors: What Is The Evidence?	A. Shatilla (AE)
10:15-10:30	Coffee Break	
10:30-12:00		
Nursing Session II		
<i>Chair: J. Massouh (AE)</i>		
10:30-11:15	Escalation and De-escalation: Case-based Discussion	S. Mrabet (TN)
11:15-12:00	Continuing Nursing Education: MS NURSE PRO, A Gateway to Professional MS Care	P. Eelen (BE)
12:00-14:00	Lunch Break	
14:00-14:30		
Nursing Satellite Symposium I hosted by Novartis		
<i>Chair: J. Massouh (AE)</i>		
14:00-14:30	The Evolving Role of the MS Nurse	P. Eelen (BE) & G. Lee (AE)
14:30-15:00		
Nursing Satellite Symposium II hosted by Roche		
14:30-15:00	Innovations in MS Treatments	G. Lee (AE)
15:00-15:30		
Nursing Satellite Symposium III hosted by Merck		
15:00-15:30	Role of Immuno-Reconstitution Therapies (IRT) in MS Management	S. Noori (AE)
15:30-16:00		
Nursing Satellite Symposium IV hosted by Biogen		
15:30-16:00	Measuring Novel Efficacy Endpoints and Convenience with Tysabri SC	G. Lee (AE)
16:00-16:30		
Nursing Satellite Symposium V hosted by AstraZeneca		
16:00-16:30	Advancements in NMO/MSD Diagnosis & Management	G. Lee (AE)

SCIENTIFIC PROGRAM



الجمعية
الوطنية للتصلب
National المتعدد
Multiple Sclerosis
Society

MSIF SESSION IN COLLABORATION WITH THE NATIONAL MS SOCIETY UAE SATURDAY, DECEMBER 9, 2023 MEETING ROOM 2

09:00-10:15 Session I: Focus on the National MS Society UAE <i>Chairs: F. Al Kaabi (AE) & Z. Burr (UK)</i>		
09:00-09:10	Welcome and Introduction	F. Al Kaabi (AE)
09:10-09:30	Keynote: Overview of the National MS Society UAE	F. Al Kaabi (AE)
09:30-09:50	Improving Access to Information in the UAE and the Wider Region	G. Al Ali (AE)
09:50-10:15	Q&A with the National MS Society UAE- moderated by F. Al Kaabi (AE) & G. Al Ali (AE)	
10:15-10:45	Coffee Break	
10:45-12:15 Session II: Key Research Updates <i>Chair: Z. Burr (UK)</i>		
10:45-11:15	Overview of the Progressive MS Alliance	T. Coetzee (US)
11:15-12:15	Key Research Updates from the MENACTRIMS Congress 2023	R. Alroughani (KW)
12:15-14:00	Lunch Break	
14:00-15:30 Session III: Access to MS Treatments <i>Chair: J. Laurson-Doube (UK)</i>		
14:00-14:30	MENA Access to Treatment Charter	P. Arce-Casillas (UK)
14:30-15:15	Using MSIF and MENACTRIMS Advocacy Tools	J. Laurson-Doube (UK)
15:15-15:30	Case Study from Morocco: How to use the WHO EML to cover the cost of MS treatment by the health system	N. El Abkari (MA)
16:00 - 17:00 Session IV: Access to MS Treatments <i>Chair: J. Laurson-Doube (UK)</i>		
16:00 -16:15	Case Study from UAE: Developing National Treatment Guidelines	A. Shatilla (AE) & Y. Mitwally (AE)
16:15-17:00	Q&A- moderated by J. Laurson-Doube (UK)	